Category: Useful Links – Info pages


Leukemia Research Trials.

By Joyce Vazq,

Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) Description – This is a phase I/II trial which studies the side effects and best dose of vorinostat and to see how well it works when given together with bortezomib and combination chemotherapy in treating infants with newly diagnosed acute lymphoblastic leukemia. Bortezomib and vorinostat may  … Read more

Leukemia Specialists.

By Joyce Vazq,

Dr. Peter G. Steinherz, MD Dr. Steinherz is a Pediatric Hematologic Oncologist and Director of the Leukemia and Lymphoma Studies at Memorial Sloan-Kettering Cancer Center. He was among the founders of Camp Simcha. During his 30-year tenure at MSKCC, Dr. Steinherz and his colleagues have developed new treatment protocols that have improved the survival rates  … Read more

Childhood Cancer in a nutshell.

By Joyce Vazq,

  Cancer.net is an excellent source of information. They have a youtube channel that provides oncologist-approved information to help patients and families. Dr. Michael Link, specialized in pediatric hematology-oncology explains to us what is childhood cancer in a nutshell.     Progress in the treatment of childhood cancer is one of the great success stories  … Read more

A potential new target for treatment of diffuse intrinsic pontine glioma (DIPG).

By Joyce Vazq,

There are some childhood cancers that have experienced few treatment advances in the past decades. The lack of effective treatment options can be a nightmare for patients and their families. The slow pace of translation for promising research from the laboratory to the clinic has created a “pre-clinical gap” meaning that basic scientific research is  … Read more

Genome sequencing of cancer survivors.

By Joyce Vazq,

St. Jude Children’s Research Hospital completed the first whole-genome sequencing of cancer survivors and the conclusions where that 12% of childhood cancer survivors carry germline mutations that put them at increased risk of developing cancer later in life. Researchers recommended expanding genetic screening and counseling to: Childhood cancer survivors who have been diagnosed with second cancers  … Read more

Personalized medicine for brain tumors.

By Joyce Vazq,

The Pacific Pediatric Neuro-Oncology Consortium (PNOC) is a network of more than 20 children’s hospitals that conduct clinical trials of new therapies for children with brain tumors with the mission to identify personalized treatment challenges. PNOC was formed to provide children with brain tumors access to individual and personalized treatment based on the molecular biology  … Read more

More about Neuroendocrine Tumors…

By Joyce Vazq,

Many patients diagnosed with a neuroendocrine tumor claimed that this video helped them to learn and understand deeply about their condition. For this reason, we want to share with you this lecture about Neuroendocrine Tumors (NETs) from the Royal Free London NHS Foundation Trust given by Dr. Christos Toumpanakis and Jorge Garcia-Hernandez. Eventhoug is not specifically  … Read more

Intra-arterial chemotherapy for Retinoblastoma.

By Joyce Vazq,

What is intra-arterial chemotherapy?  Intra-arterial chemotherapy refers to a novel treatment that consists in delivering the chemo directly into the artery feeding the eye, because of this doctors can use much smaller doses of chemo drugs (less than 10% of the doses used for systemic chemo). Therefore, there are significantly fewer side effects from the  … Read more

About mice and cancer-treatment.

By Oded,

champions

This link is to an article that Suzie Siegel wrote about the upcoming clinical trial using mice to help doctors choose the right treatment for someone with advanced soft-tissue sarcoma:  http://sarcomaalliance.blogspot.com/ Cancer treatments have been tested on mice for years.Now a new technology uses mice to determine which treatments may best fight an individual patient’s sarcoma.  … Read more

About THE NEW PD-1 and PD-L1 DRUG

By Oded,

What Are PD-1 and PD-L1? Programmed death 1 (PD-1) is an immune inhibitory receptor expressed on several immune cells, particularly cytotoxic T cells.[1] It interacts with two ligands, programmed death ligand 1 (PD-L1) (B7-H1, CD274) and PD-L2 (B7-DC). While PD-L2 is expressed primarily on macrophages and dendritic cells, PD-L1 is expressed on tumor cells, as  … Read more